Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.
The user is questioning if they are experiencing hair regrowth after using topical Minoxidil for 4-5 months, noting increased body hair but uncertain head hair changes. Other users suggest the appearance is due to a natural cowlick rather than balding.
Salicylic acid in Nioxin shampoo may reduce minoxidil effectiveness by inhibiting sulfotransferase activity, potentially causing hair loss. Users suggest stopping salicylic acid use or trying alternative treatments like high-concentration tretinoin or medicated minoxidil/finasteride shampoos.
The user experienced thicker and healthier hair after 1.5 years of using finasteride daily, with no side effects. They plan to start minoxidil to enhance regrowth.
A new supplement for hair growth combines black rice, prickly pear, and saw palmetto, showing promising results in increasing hair density and reducing hair loss. The supplement is considered a drug-free alternative to traditional treatments like minoxidil and finasteride.
A 21-year-old male is using a topical treatment for hair loss, including Dutasteride, Minoxidil, Tretinoin, Ketoconazole, and Hydrocortisone, along with derma rolling. He reports no side effects from the treatment and seeks feedback on its effectiveness for hair regrowth.
Derma rollers may cause scarring alopecia, leading some to prefer dermastamps or dermapens for microneedling. Combining minoxidil with microneedling is effective, but proper technique and healing time are essential to prevent damage.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
A hair loss treatment plan includes finasteride, dutasteride, RU58841, pyrilutamide, minoxidil, and microneedling to inhibit DHT and promote hair growth. It also recommends supplements like Reishi and Lion’s Mane mushrooms, and a shampoo with ketoconazole, caffeine, and melatonin.
The conversation discusses microneedling for hair loss, with the original poster experiencing pinpoint bleeding after using needles of 1.25mm and 0.5mm, possibly due to adding GHK-Cu to their treatment regimen. They are inquiring if others bleed at similar depths.
Fibrin hydrogels, when combined with stem cells, can induce hair follicle regeneration and show potential for treating alopecia. The study demonstrated successful hair growth in mice without adverse effects.
Minoxidil may cause skin issues like wrinkles and dark undereyes, possibly due to alcohol content. Alternatives include collagen supplements, vitamin C, and skincare products; some users prefer finasteride for hair loss without these side effects.
Finasteride caused brain fog and reduced the effectiveness of mirtazapine for the user, leading them to stop finasteride and notice improvements in motivation and focus. The user suggests that finasteride might be incompatible with mirtazapine for some people and recommends mirtazapine for those experiencing mental fog from finasteride.
Minoxidil may cause facial bloat, wrinkles, and dark circles, with some users experiencing these side effects quickly. Finasteride can cause painful ejaculations and watery semen, but concerns about penis shrinkage are generally unfounded.
The user started with oral minoxidil and switched to 2.5mg dutasteride, experiencing significant hair growth without side effects. They believe dutasteride has fewer side effects than finasteride due to its action on both type 1 and 2 5-alpha reductase enzymes.
The user switched from finasteride to dutasteride but experienced more hair thinning, questioning whether to switch back. Others shared similar experiences, suggesting patience or considering different dosages, while some noted potential issues with testosterone levels.
The conversation expresses skepticism about the effectiveness of new hair loss treatments, comparing them to 2% minoxidil and criticizing the lack of substantial data. Users doubt the claims of a non-hormonal treatment and mention previous disappointments with products like JXL-069.
PP405 shows promise in reactivating dormant hair follicles, with early trials indicating some success, but it is not yet a proven treatment for hair loss. Users are advised to be cautious with unverified versions, and further research is needed to confirm its effectiveness compared to treatments like minoxidil and finasteride.
A 26-year-old shared their successful hair regrowth journey using finasteride, minoxidil, and dutasteride, along with a custom minoxidil solution containing progesterone, cortisone, alpha 5 estradiol, menthol, caffeine, and melatonin. They experienced no side effects but noted that stopping the medications would reverse the progress.
VDPHL01, an extended-release oral minoxidil tablet, showed promising results in improving hair coverage for 79 to 86% of men in a trial, with fewer side effects compared to standard doses. Many users prefer oral minoxidil over topical due to ease of use and fewer side effects, especially for those with pets.
The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.
The conversation discusses a user's 9-month progress using topical finasteride (0.05%) and minoxidil (5%) with microneedling for hair loss, noting some improvement without side effects. Suggestions include trying oral treatments or switching to topical dutasteride for potentially better results.
Pyrilutamide is effective for mild hair loss, especially when finasteride isn't an option, but it's less effective than finasteride and requires consistent application. It's best for early-stage hair loss and works well in combination with other treatments like minoxidil.
A 34-year-old started treating hair loss with finasteride but switched to dutasteride due to cost and efficacy, experiencing some side effects. They use topical minoxidil twice daily and report positive progress after four months.
Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.
The conversation discusses hair regrowth progress using a topical solution of minoxidil and finasteride. Users express surprise and curiosity about the results, with some noting dramatic changes and others asking about specific product details and concentrations.
The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.
The user showed 2-3 years of hair regrowth progress using oral finasteride, topical minoxidil, and microneedling. They plan to switch to oral dutasteride and Liposomal Minoxidil Sulfate for better results.
Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.
Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.